Tango Therapeutics to Present Cancer Data in Madrid
The company will debut Phase 1/2 trial findings at the ESMO Congress 2026 beginning on October 23.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Do you trust biotechnology company clinical data updates to inform your investment decisions?
Tango Therapeutics will showcase new clinical study data regarding vopimetostat combinations at the ESMO Congress 2026 in Madrid. The presentation scheduled for October 25 will highlight research on patients with specific genetic mutations.
Why it matters
This presentation provides insight into the progress of synthetic lethality drug targets for challenging cancer types including metastatic PDAC and NSCLC. It marks a key moment for evaluating the efficacy of these novel treatment combinations.
The clinical study is cataloged as Abstract 3149P and utilizes data collected through an April 3, 2026, cutoff. The findings will be shared through a poster presentation during the conference.
The players
Tango Therapeutics
A biotechnology company that discovers and develops novel medicines using the principle of synthetic lethality.
Alexander I. Spira
An oncology specialist who will present the poster findings at the international medical congress.
The details
Tango Therapeutics is testing vopimetostat in combination with daraxonrasib or zoldonrasib to address specific genetic vulnerabilities in cancer patients. The company utilizes the principle of synthetic lethality to identify these targeted therapeutic approaches.
Timeline
April 3, 2026: Data cutoff date for the abstract.
October 19, 2026: Abstracts become available on the ESMO website.
October 23, 2026: Investor webcast and the start of the ESMO Congress.
October 25, 2026: Poster presentation by Alexander I. Spira.
October 27, 2026: Conclusion of the ESMO Congress.
The Big Picture
The upcoming presentation at the ESMO Congress follows the standard pattern for global oncology forums to disseminate phase-trial updates. This event serves as a critical benchmark for validating advancements in targeted genetic therapies.
The results of this study could eventually influence new treatment options for patients diagnosed with metastatic PDAC or NSCLC. These findings help define the potential future role of vopimetostat-based combinations in clinical practice.
The takeaway
Advancements in synthetic lethality research reflect a shift toward highly personalized oncology treatments. Readers interested in medical innovation should monitor how these trial results eventually translate into standardized therapeutic pathways.
What happens next
Tango Therapeutics will host an investor webcast on October 23, 2026, to discuss the findings, with a replay available on the company website for at least 30 days.
Further reading
Learn more about ongoing developments in this field at the Cancer section.
More information
View upcoming investor updates and trial disclosures at the Tango Therapeutics investor events portal.
Live Poll
Do you trust biotechnology company clinical data updates to inform your investment decisions?
